Bristol-Myers Squibb Overview
Latest ROE for Bristol-Myers Squibb: 41.59% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow41.59%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for BMY is 41.59%. That is above the Healthcare sector average of 29.33%. Investors often review this figure alongside Bristol-Myers Squibb's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, BMY currently prints 41.59% for ROE, while the sector average sits near 29.33%. That is roughly 41.8% above the sector mean. Large gaps often invite a closer look at Bristol-Myers Squibb's growth, margins, and balance sheet.
Return on Equity shows how effectively Bristol-Myers Squibb converts resources into returns. At 41.59%, BMY may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting BMY's ROE (41.59%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Bristol-Myers Squibb's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
